MaaT Pharma (MAAT) Posts H1 Loss, Extends Cash Runway To December 2026
MaaT Pharma reported H1 2026 revenue of €1.1M (vs €2.4M in H1 2025) and operating loss of €18.3M (vs €15.1M), with cash of €17.1M at June 30 and cash runway now extended to December 2026.Material DetailsContext by AI AnalystThis is a mid-course update after a negative CHMP opinion on MaaT013, showi…